Baseline characteristics, management, and outcomes of 55,270 children and adolescents diagnosed with COVID-19 and 1,952,693 with influenza in France, Germany, Spain, South Korea and the United States : an international network cohort study
Objectives To characterize the demographics, comorbidities, symptoms, in-hospital treatments, and health outcomes among children/adolescents diagnosed or hospitalized with COVID-19. Secondly, to describe health outcomes amongst children/adolescents diagnosed with previous seasonal influenza. Design International network cohort. Setting Real-world data from European primary care records (France/Germany/Spain), South Korean claims and US claims and hospital databases. Participants Diagnosed and/or hospitalized children/adolescents with COVID-19 at age <18 between January and June 2020; diagnosed with influenza in 2017-2018. Main outcome measures Baseline demographics and comorbidities, symptoms, 30-day in-hospital treatments and outcomes including hospitalization, pneumonia, acute respiratory distress syndrome (ARDS), multi-system inflammatory syndrome (MIS-C), and death. Results A total of 55,270 children/adolescents diagnosed and 3,693 hospitalized with COVID-19 and 1,952,693 diagnosed with influenza were studied. Comorbidities including neurodevelopmental disorders, heart disease, and cancer were all more common among those hospitalized vs diagnosed with COVID-19. The most common COVID-19 symptom was fever. Dyspnea, bronchiolitis, anosmia and gastrointestinal symptoms were more common in COVID-19 than influenza. In-hospital treatments for COVID-19 included repurposed medications (<10%), and adjunctive therapies: systemic corticosteroids (6.8% to 37.6%), famotidine (9.0% to 28.1%), and antithrombotics such as aspirin (2.0% to 21.4%), heparin (2.2% to 18.1%), and enoxaparin (2.8% to 14.8%). Hospitalization was observed in 0.3% to 1.3% of the COVID-19 diagnosed cohort, with undetectable (N<5 per database) 30-day fatality. Thirty-day outcomes including pneumonia, ARDS, and MIS-C were more frequent in COVID-19 than influenza. Conclusions Despite negligible fatality, complications including pneumonia, ARDS and MIS-C were more frequent in children/adolescents with COVID-19 than with influenza. Dyspnea, anosmia and gastrointestinal symptoms could help differential diagnosis. A wide range of medications were used for the inpatient management of pediatric COVID-19.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2020 |
|---|---|
| Enthalten in: |
medRxiv : the preprint server for health sciences - (2020) vom: 30. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Duarte-Salles, Talita [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 09.11.2023 published: Electronic UpdateIn: Pediatrics. 2021 Sep;148(3):. - PMID 34049958 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2020.10.29.20222083 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317083821 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317083821 | ||
| 003 | DE-627 | ||
| 005 | 20231225162503.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.10.29.20222083 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1056.xml |
| 035 | |a (DE-627)NLM317083821 | ||
| 035 | |a (NLM)33140074 | ||
| 035 | |a (PII)2020.10.29.20222083 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Duarte-Salles, Talita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Baseline characteristics, management, and outcomes of 55,270 children and adolescents diagnosed with COVID-19 and 1,952,693 with influenza in France, Germany, Spain, South Korea and the United States |b an international network cohort study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 09.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Pediatrics. 2021 Sep;148(3):. - PMID 34049958 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Objectives To characterize the demographics, comorbidities, symptoms, in-hospital treatments, and health outcomes among children/adolescents diagnosed or hospitalized with COVID-19. Secondly, to describe health outcomes amongst children/adolescents diagnosed with previous seasonal influenza. Design International network cohort. Setting Real-world data from European primary care records (France/Germany/Spain), South Korean claims and US claims and hospital databases. Participants Diagnosed and/or hospitalized children/adolescents with COVID-19 at age <18 between January and June 2020; diagnosed with influenza in 2017-2018. Main outcome measures Baseline demographics and comorbidities, symptoms, 30-day in-hospital treatments and outcomes including hospitalization, pneumonia, acute respiratory distress syndrome (ARDS), multi-system inflammatory syndrome (MIS-C), and death. Results A total of 55,270 children/adolescents diagnosed and 3,693 hospitalized with COVID-19 and 1,952,693 diagnosed with influenza were studied. Comorbidities including neurodevelopmental disorders, heart disease, and cancer were all more common among those hospitalized vs diagnosed with COVID-19. The most common COVID-19 symptom was fever. Dyspnea, bronchiolitis, anosmia and gastrointestinal symptoms were more common in COVID-19 than influenza. In-hospital treatments for COVID-19 included repurposed medications (<10%), and adjunctive therapies: systemic corticosteroids (6.8% to 37.6%), famotidine (9.0% to 28.1%), and antithrombotics such as aspirin (2.0% to 21.4%), heparin (2.2% to 18.1%), and enoxaparin (2.8% to 14.8%). Hospitalization was observed in 0.3% to 1.3% of the COVID-19 diagnosed cohort, with undetectable (N<5 per database) 30-day fatality. Thirty-day outcomes including pneumonia, ARDS, and MIS-C were more frequent in COVID-19 than influenza. Conclusions Despite negligible fatality, complications including pneumonia, ARDS and MIS-C were more frequent in children/adolescents with COVID-19 than with influenza. Dyspnea, anosmia and gastrointestinal symptoms could help differential diagnosis. A wide range of medications were used for the inpatient management of pediatric COVID-19 | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Vizcaya, David |e verfasserin |4 aut | |
| 700 | 1 | |a Pistillo, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Casajust, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Sena, Anthony G |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, Lana Yin Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Prats-Uribe, Albert |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Waheed-Ul-Rahman |e verfasserin |4 aut | |
| 700 | 1 | |a Alshammari, Thamir M |e verfasserin |4 aut | |
| 700 | 1 | |a Alghoul, Heba |e verfasserin |4 aut | |
| 700 | 1 | |a Alser, Osaid |e verfasserin |4 aut | |
| 700 | 1 | |a Burn, Edward |e verfasserin |4 aut | |
| 700 | 1 | |a You, Seng Chan |e verfasserin |4 aut | |
| 700 | 1 | |a Areia, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Blacketer, Clair |e verfasserin |4 aut | |
| 700 | 1 | |a DuVall, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Falconer, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez-Bertolin, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Fortin, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Golozar, Asieh |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Mengchun |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Eng Hooi |e verfasserin |4 aut | |
| 700 | 1 | |a Huser, Vojtech |e verfasserin |4 aut | |
| 700 | 1 | |a Iveli, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Morales, Daniel R |e verfasserin |4 aut | |
| 700 | 1 | |a Nyberg, Fredrik |e verfasserin |4 aut | |
| 700 | 1 | |a Posada, Jose D |e verfasserin |4 aut | |
| 700 | 1 | |a Recalde, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Roel, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Schilling, Lisa M |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Nigam H |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Karishma |e verfasserin |4 aut | |
| 700 | 1 | |a Suchard, Marc A |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Andrew E |e verfasserin |4 aut | |
| 700 | 1 | |a Reich, Christian G |e verfasserin |4 aut | |
| 700 | 1 | |a Hripcsak, George |e verfasserin |4 aut | |
| 700 | 1 | |a Rijnbeek, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Ryan, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Kostka, Kristin |e verfasserin |4 aut | |
| 700 | 1 | |a Prieto-Alhambra, Daniel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2020) vom: 30. Okt. |w (DE-627)NLM310900166 |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g day:30 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.10.29.20222083 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 30 |c 10 | ||